Your search returned 1978 results.

Results
	581.	Circulating PCSK9 levels and CETP plasma activity are independently associated in patients with metabolic diseases. [electronic resource] by Girona, Josefa Ibarretxe, Daiana Plana, Nuria Guaita-Esteruelas, Sandra Amigo, Nuria Heras, Mercedes Masana, Luis Producer: 20170209 In: Cardiovascular diabetology vol. 15 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)
	582.	PCSK9: Regulation and Target for Drug Development for Dyslipidemia. [electronic resource] by Burke, Amy C Dron, Jacqueline S Hegele, Robert A Huff, Murray W Producer: 20171116 In: Annual review of pharmacology and toxicology vol. 57 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)
	583.	Proprotein convertase subtilisin/kexin type 9 inhibits interferon β expression through interacting with ATF-2. [electronic resource] by Li, Zhubing Liu, Qiang Producer: 20190624 In: FEBS letters vol. 592 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)
	584.	[PCSK9 inhibitors (PCSK9i), a new opportunity for cardiovascular prevention: clinical and regulatory aspects and access to therapy.] [electronic resource] by Arca, Marcello Producer: 20200325 In: Recenti progressi in medicina vol. 110 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)
	585.	Plasma PCSK9 is associated with age, sex, and multiple metabolic markers in a population-based sample of children and adolescents. [electronic resource] by Baass, Alexis Dubuc, Geneviève Tremblay, Michel Delvin, Edgard E O'Loughlin, Jennifer Levy, Emile Davignon, Jean Lambert, Marie Producer: 20090916 In: Clinical chemistry vol. 55 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)
	586.	PCSK9 siRNA suppresses the inflammatory response induced by oxLDL through inhibition of NF-κB activation in THP-1-derived macrophages. [electronic resource] by Tang, Zhihan Jiang, Lu Peng, Juan Ren, Zhong Wei, Dangheng Wu, Chunyang Pan, Lihong Jiang, Zhisheng Liu, Lushan Producer: 20130524 In: International journal of molecular medicine vol. 30 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)
	587.	A two-step binding model of PCSK9 interaction with the low density lipoprotein receptor. [electronic resource] by Yamamoto, Taichi Lu, Christine Ryan, Robert O Producer: 20110411 In: The Journal of biological chemistry vol. 286 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)
	588.	PCSK9 inhibition: current concepts and lessons from human genetics. [electronic resource] by Rodriguez, Fatima Knowles, Joshua W Producer: 20151113 In: Current atherosclerosis reports vol. 17 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)
	589.	[Hyperlipidemia. New treatment option with Evolocumab]. [electronic resource] by Ecker-Schlipf, Barbara Producer: 20140820 In: Medizinische Monatsschrift fur Pharmazeuten vol. 37 Availability: No items available. Save to lists Add to cart (remove)
	590.	PCSK9 inhibitor access barriers-issues and recommendations: Improving the access process for patients, clinicians and payers. [electronic resource] by Baum, Seth J Toth, Peter P Underberg, James A Jellinger, Paul Ross, Joyce Wilemon, Katherine Producer: 20170621 In: Clinical cardiology vol. 40 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)
	591.	Practical Considerations for the Use of Subcutaneous Treatment in the Management of Dyslipidaemia. [electronic resource] by Boccara, Franck Dent, Ricardo Ruilope, Luis Valensi, Paul Producer: 20180201 In: Advances in therapy vol. 34 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)
	592.	Statins and Their Effect on PCSK9-Impact and Clinical Relevance. [electronic resource] by Taylor, Beth A Thompson, Paul D Producer: 20170523 In: Current atherosclerosis reports vol. 18 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)
	593.	Functional characterization of mutant genes associated with autosomal dominant familial hypercholesterolemia: integration and evolution of genetic diagnosis. [electronic resource] by Di Taranto, M D D'Agostino, M N Fortunato, G Producer: 20160907 In: Nutrition, metabolism, and cardiovascular diseases : NMCD vol. 25 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)
	594.	In silico Screening of Chemical Libraries to Develop Inhibitors That Hamper the Interaction of PCSK9 with the LDL Receptor. [electronic resource] by Min, Dong-Kook Lee, Hyun-Sook Lee, Narae Lee, Chan Joo Song, Hyun Joo Yang, Ga Eul Yoon, Dojun Park, Sahng Wook Producer: 20160108 In: Yonsei medical journal vol. 56 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)
	595.	Proprotein Convertase Subtilisin/Kexin Type 9 Inhibition--The Dream of Translational Medicine. [electronic resource] by Uppugunduri, Chakradhara Rao S George, Melvin Producer: 20161213 In: Journal of cardiovascular pharmacology vol. 67 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)
	596.	Design of Organo-Peptides As Bipartite PCSK9 Antagonists. [electronic resource] by Burdick, Daniel J Skelton, Nicholas J Ultsch, Mark Beresini, Maureen H Eigenbrot, Charles Li, Wei Zhang, Yingnan Nguyen, Huy Kong-Beltran, Monica Quinn, John G Kirchhofer, Daniel Producer: 20210209 In: ACS chemical biology vol. 15 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)
	597.	Novel mutations of the PCSK9 gene cause variable phenotype of autosomal dominant hypercholesterolemia. [electronic resource] by Allard, Delphine Amsellem, Sabine Abifadel, Marianne Trillard, Mélanie Devillers, Martine Luc, Gérald Krempf, Michel Reznik, Yves Girardet, Jean-Philippe Fredenrich, Alexandre Junien, Claudine Varret, Mathilde Boileau, Catherine Benlian, Pascale Rabès, Jean-Pierre Producer: 20060613 In: Human mutation vol. 26 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)
	598.	A PCSK9 missense variant associated with a reduced risk of early-onset myocardial infarction. [electronic resource] by Kathiresan, Sekar Producer: 20080604 In: The New England journal of medicine vol. 358 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)
	599.	Inhibition of pro-protein convertase subtilisin kexin 9 [corrected] (PCSK-9) as a treatment for hyperlipidaemia. [electronic resource] by Wierzbicki, Anthony S Hardman, Timothy C Viljoen, Adie Producer: 20120807 In: Expert opinion on investigational drugs vol. 21 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)
	600.	The M2 module of the Cys-His-rich domain (CHRD) of PCSK9 protein is needed for the extracellular low-density lipoprotein receptor (LDLR) degradation pathway. [electronic resource] by Saavedra, Yascara Grisel Luna Day, Robert Seidah, Nabil G Producer: 20130226 In: The Journal of biological chemistry vol. 287 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)

First
Previous
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
Next
Last

Refine your search

Availability

Authors

Topics

Languages

Your search returned 1978 results.